

AMENDMENTS TO THE CLAIMS

Please amend the claims as shown in the marked-up copy to read as follows:

1. – 20. (Cancelled)

21. (New) A method for detecting binding of von Willebrand factor and glycoprotein Ib or inhibition of the binding, comprising the steps of:

binding a chimeric protein that consists of an Fc region of immunoglobulin molecule fused at its amino terminus to a partial protein comprising a von Willebrand factor binding site of glycoprotein Ib α chain at its carboxyl terminus or to von Willebrand factor immobilized in a reaction vessel, and

detecting said Fc region of the immunoglobulin molecule, and

correlating said detecting of said Fc region of the immunoglobulin molecule with the binding of von Willebrand factor and glycoprotein Ib or inhibition of the binding,

wherein said von Willebrand factor binding site is a region contained in the amino acid sequences of the amino acid residues 251-285 of glycoprotein Ib α chain.

22. (New) The method according to claim 21, wherein said immunoglobulin molecule is derived from mouse.

23. (New) The method according to claim 21, wherein said immunoglobulin molecule is derived from human.

24. (New) The method according to claim 21, wherein said immunoglobulin molecule is derived from human, and wherein said von Willebrand factor binding site is a region contained in the amino acid sequences of the amino acid residues 1-293 of glycoproteins Ib α chain.

25. (New) The method according to claim 21, wherein said immunoglobulin molecule is derived from human, and wherein said von Willebrand factor binding site is a

region contained in the amino acid sequences of the amino acid residues 1-319 of glycoproteins Iba chain.

26. (New) A method for detecting binding of von Willebrand factor and glycoprotein Ib or inhibition of the binding, comprising the steps of:

immobilizing a chimeric protein that consists of an Fc region of immunoglobulin molecule fused at its amino terminus to a partial protein comprising a von Willebrand factor binding site of glycoprotein Ib chain at its carboxyl terminus in a reaction vessel,

binding an unlabeled von Willebrand factor or a labeled von Willebrand factor to the chimeric protein, wherein said labeled von Willebrand factor has been labeled with a labeling substance,

detecting bound unlabeled von Willebrand factor or said labeling substance, and

correlating said detecting with the binding of von Willebrand factor and glycoprotein Ib or inhibition of the binding by comparing said detecting in the presence of an inhibiting substance to detecting in the absence of an inhibiting substance,

wherein said von Willebrand factor binding site is a region contained in the amino acid sequences of the amino acid residues 251-285 of glycoprotein Iba chain.

27. (New) The method according to claim 26, wherein said immunoglobulin molecule is derived from mouse.

28. (New) The method according to claim 26, wherein said immunoglobulin molecule is derived from human.

29. (New) The method according to claim 26, wherein said immunoglobulin molecule is derived from human, and wherein said von Willebrand factor binding site is a region contained in the amino acid sequences of the amino acid residues 1-293 of glycoproteins Iba chain.

30. (New) The method according to claim 26, wherein said immunoglobulin molecule is derived from human, and wherein said von Willebrand factor binding site is a region contained in the amino acid sequences of the amino acid residues 1-319 of glycoproteins Iba chain.

31. (New) A chimeric protein, which consists of an Fc region of immunoglobulin molecule fused at its amino terminus to a partial protein comprising a von Willebrand factor binding site of glycoprotein Iba chain at its carboxyl terminus,
wherein the immunoglobulin is derived from human.

32. (New) The chimeric protein according to claim 31, wherein said von Willebrand factor binding site is a region contained in the amino acid sequences of the amino acid residues 251-285 of glycoprotein Iba chain.

33. (New) The chimeric protein according to claim 31, wherein said von Willebrand factor binding site is a region contained in the amino acid sequences of the amino acid residues 1-293 of glycoproteins Iba chain.

34. (New) The chimeric protein according to claim 31, wherein said von Willebrand factor binding site is a region contained in the amino acid sequences of the amino acid residues 1-319 of glycoproteins Iba chain.

35. (New) A kit for measuring glyco-calicin based on inhibition of a reaction of von Willebrand factor and glycoprotein Ib, comprising von Willebrand factor and a chimeric protein that consists of an Fc region of immunoglobulin molecule fused at its amino terminus to a partial protein comprising a von Willebrand factor binding site of glycoprotein Iba chain at its carboxyl terminus,

wherein said von Willebrand factor binding site is a region contained in the amino acid sequences of the amino acid residues 251-285 of glycoprotein Iba chain.

SUPPORT FOR THE AMENDMENTS

Claims 11 and 19 have been amended.

Claims 22-27 have been added.

The amendment of Claims 11 and 19 find support in the claims and the specification as originally filed, in particular at page 34, line 18 to page 35, line 2. The amendment of Claim 11 serves to obviate the criticisms outlined on page 3 of paper number 12 (numbered paragraph 5). Moreover, the amendment of Claim 11 is for clarity sake only and, in no way, is meant to limit and/or alter the scope of this claim or the claims dependent therefrom. Support for new Claims 22-27 can be found in Claims 19 and 20, as originally filed.

No new matter has been added.